Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

DSpace Repository

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

Author: Weisel, Katja; Majer, Istvan; DeCosta, Lucy; Oriol, Albert; Goldschmidt, Hartmut; Ludwig, Heinz; Campioni, Marco; Szabo, Zsolt; Dimopoulos, Meletios
Tübinger Autor(en):
Weisel, Katja
Published in: Leukemia & Lymphoma (2020), Bd. 61, H. 1, S. 37-46
Verlagsangabe: Taylor & Francis Ltd
Language: English
Full text: http://dx.doi.org/10.1080/10428194.2019.1648806
ISSN: 1029-2403
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Note: "Published online: 22 Oct 2019"
Show full item record

This item appears in the following Collection(s)